Wall Street analyst estimates for Puma Biotechnology, Inc. (PBYI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 8 |
| Sell | 4 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.20 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.11 | ||
| 2026-08-06 | $0.19 | $0.04 | +375.0% |
| 2026-05-07 | $-0.04 | $-0.13 | +69.2% |
| 2026-02-26 | $0.29 | $0.24 | +20.8% |
| 2025-11-06 | $0.21 | $0.09 | +133.3% |
| 2025-08-07 | $0.15 | $0.11 | +36.4% |
| 2025-05-08 | $0.10 | $0.02 | +400.0% |
| 2025-02-27 | $0.43 | $0.10 | +330.0% |
Valuation Ratios
| P/E Ratio | 16.72 |
| Price / Book | 3.30 |
| EV / EBITDA | 9.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $27.7M | $251.0M | $272.3M | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Cost of Revenue | $1.1M | $5.6M | $34.6M | $36.8M | $39.4M | $63.7M | $55.1M | $62.7M | $64.4M | $58.2M |
| Gross Profit | -$1.1M | $22.1M | $216.4M | $235.4M | $185.7M | $189.5M | $172.9M | $173.0M | $166.1M | $170.2M |
| Research & Development | $222.8M | $207.8M | $164.9M | $132.9M | $97.7M | $71.9M | $52.2M | $50.4M | $54.9M | $62.1M |
| Selling, General & Admin | $53.8M | $106.7M | $146.2M | $141.6M | $118.5M | $116.3M | $90.0M | $89.3M | $80.2M | $71.2M |
| Operating Expenses | $276.6M | $314.5M | $311.1M | $311.0M | $216.1M | $188.2M | $149.2M | $140.3M | $135.1M | $132.9M |
| Operating Income | -$276.6M | -$292.4M | -$94.7M | -$75.6M | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| EBITDA | -$275.4M | -$288.4M | -$95.2M | -$52.4M | -$35.7M | -$4.7M | $21.9M | $47.5M | $48.1M | $53.3M |
| Interest Expense | $958000 | $720000 | $11.0M | $15.0M | $14.0M | $12.8M | $11.6M | $13.3M | $12.5M | $6.6M |
| Pre-tax Income | -$276.0M | -$292.0M | -$113.6M | -$75.5M | -$59.8M | -$28.8M | $457000 | $22.7M | $24.1M | $35.8M |
| Income Tax | -$2.1M | -$2.2M | -$7.9M | $53000 | $207000 | $324000 | $455000 | $1.1M | -$6.2M | $4.7M |
| Net Income | -$276.0M | -$292.0M | -$113.6M | -$75.6M | -$60.0M | -$29.1M | $2000 | $21.6M | $30.3M | $31.1M |
| EPS | $-8.29 | $-7.86 | $-2.99 | $-2.13 | $-1.52 | $-0.72 | $0.02 | $0.46 | $0.62 | $0.62 |
| EPS (Diluted) | $-8.29 | $-7.86 | $-2.99 | $-2.13 | $-1.52 | $-0.72 | $0.02 | $0.45 | $0.62 | $0.61 |
| Shares Outstanding (Diluted) | $33.3M | $37.2M | $37.9M | $38.8M | $39.6M | $40.6M | $44.9M | $47.6M | $49.1M | $50.7M |
Price
| Price | $9.39 |
| Market Cap | $478M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABEO · ALLO · ARCT · AVIR · ELDN · HUMA · SGMT
Explore sector: Healthcare · Biotechnology
More sections of PBYI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks